QIBA FDG-PET Biomarker Committee (BC) Call
03 November 2017 at 9 AM CT
Call Summary

In attendance:

**RSNA**

John Sunderland, PhD (Co-Chair)  
Martin Lodge, PhD  
Anne Smith, PhD  
Joe Koudelik

Scott Wollenweber, PhD (Co-Chair)  
Jayant Narang, MD  
Mitsuaki Tatsumi, MD  
Julie Lisiecki

Chris Crisman, MBA  
Nancy Obuchowski, PhD  
Timothy Turkington, PhD  

Paul Kinahan, PhD  
Eric Perlman, MD  
Xiaoyou Ying, PhD

Jeff Kolthammer, PhD

**Moderator:** Dr. Sunderland

**RSNA 2017 Meet-The-Experts (MTE) Update**

- Only 3 open presenter spots remain for the QIBA FDG-PET poster.
- Additional volunteers are needed.
- If available, please sign up via the link above for these poster sessions.

**Radiology Article Update**

- A special report article has been submitted to *Radiology* with the FDG-PET checklist
- Feedback was received from the editors on how to improve the article for possible publication
- More details are needed, keeping the viewpoint of the audience in mind
  - An introduction to quantitative imaging with practical details on how Profiles are used
  - Need high-level context regarding how / why Profiles matter, not detailed Profile specifics
- Remaining tasks are as follows:
  - Dr. Kinahan will work on literature/evidence grading and responses to reviewers for BC review
  - Comments to be sent to Dr. Kinahan regarding the lit review
  - Comments to be sent to Dr. Kinahan by November 10th regarding the response to reviewers
  - Target date to return with edits to *Radiology* editors: November 17th
- If accepted, supplementary materials related to the Profile may be added

**FDG-PET Breakout Session for RSNA 2017**

- Those who are attending the RSNA 2017 meeting and have not yet RSVP’d for the QIBA Working Meeting scheduled for Wednesday, November 29th are asked to do so using the link above
- Suggested topics for the FDG-PET breakout session include:
  - *Radiology* article update – edits should be complete/submitted prior to the f2f meeting
  - Strategies to include PET-MRI and ways to collaborate to enhance the existing FDG-PET/CT Profile
    - Test-retest work with PET-MRI is being conducted by Drs. Tom Hope (UCSF) and Richard LaForest (Wash U)
    - Additional expertise is needed for this effort; active targeted recruitment to be encouraged
    - BC members will need to decide which sections of the Profile require modification, as inclusion of PET-MRI would cross all areas, including physics
    - Dr. Perlman requested that the PET-Amyloid BC leaders be included in these collaborative discussions
  - How to handle those who question the application of quantification and quantitative imaging
    - A position paper was suggested, to be literature-based regarding the value of quantitative imaging and realized clinical value
    - Dr. Sunderland suggested forming a dedicated Task Force to draft this Q-Value paper
Sustainability for future groundwork

- All are asked to think beyond the usual government funding sources for new ideas
- Dr. Perlman discussed partnerships for QIBA that are under consideration, including working with ACRES (*The Alliance for Clinical Research Excellence and Safety*) – an accreditation body
  - The FDG-PET checklist might be used in a pilot project for clinical trials
- Other biomarker committees are reaching out to like-minded organizations that share an interest in their research to consider partnerships for groundwork projects
  - FDG-PET BC members are asked to consider possible partnerships
  - This will be a topic of discussion for the f2f breakout session
  - ECOG-ACRIN efforts may be leveraged to produce test/retest data to support the Profile
    - Drs. Kinahan and Subramaniam to follow up with ECOG-ACRIN contacts over the next few weeks
- Dr. Kinahan mentioned that QIBA is also considering ways to bridge the gaps between QIBA and QIN
- Other ideas included the following:
  - Talking with QIBA industry partners to see if they may be willing to sponsor groundwork projects
  - Following up with other related societies that may have similar research interests
  - Talking with MITA
  - Considering radiotracer manufacturers as possible research sponsors
  - Following up with pharma partners and equipment manufacturers who would most benefit from QIBA’s Profiles, particularly in relation to repeatability studies and solid tumor non-lymphoma work
    - RSNA staff to provide co-chairs with a list of al QIBA pharma / equipment manufacturers across modalities to aid with inquiry

*Nuclear Medicine WebEx Schedule:*

**12/08** PET Amyloid BC
**12/15** NM Coordinating Committee

*SAVE-THE-DATE:* QIBA Working Meeting at RSNA 2017 | Wednesday, November 29, 2:30-6 pm – Lakeside Center